期刊文献+

HPLC法测定苹果酸阿莫曲坦含量的研究 被引量:1

Determination of Almotriptan Malate Tablets by HPLC
下载PDF
导出
摘要 [目的]建立一种高效液相色谱法,测定苹果酸阿莫曲坦片的含量.[方法]采用高效液相色谱法(HPLC),色谱柱为Agilent ZobaxSB C8 column(250×4.6mm,5μm);以缓冲液(取0.5g辛烷磺酸钠与5ml磷酸溶液,加水至1 000 ml,用5mol/L氢氧化钠调节pH至3.0)-乙腈作为流动相,等度洗脱,流速1.0 ml/min,柱温30℃,检测波长230 nm,选样量10μl.[结果]苹果酸阿莫曲坦的浓度在17.49~209.88 μg/ml范围内线性关系良好(Y=27.534X+9.693,r =0.999 9),高、中、低3种浓度的平均回收率(n=3)为99.23%(RSD=0.95%);中间精密度RSD =0.98% (n =6),重复性和耐用性良好.[结论]该方法简便、灵敏、准确,可作为苹果酸阿莫曲坦片含量的检验方法. [ Objecive ] To establish a HPLC method for the determination of almotriptan malate tablets. [ Method ] Using high-performance liquid chromatography, chromatographic column of Agilent zobax SB C8 column (250 ×4.6 mm, 5 μm) ; With a mixture of octane sulfonate buffer (adjusted pH to 3.0 with phosphoric acid) and acetonitrile as mobile phase, isocratic elution method, flow rate 1.0 ml/min, tempera- ture 30℃, detection wavelength 230 nm, injection 10 μl. [ Result ] Almotriptan malate concentration in the range of 17.49 to 209.88 μg/ml has a good linear relationship ( Y = 27. 534X + 9. 693, r = 0.999 9), the average recovery of high, middle, low, 3 kinds of concentration ratio ( n = 3 ) 99.23 % ( RSD = 0.95 % ) ; intermediate precision RSD = 0.98 % ( n = 6), Repeatability and durability is good. [ Conclusion ] The method is simple, sensitive, accurate, reproducible, which is suitable for the determination of almotriptan malate.
出处 《安徽农业科学》 CAS 2015年第8期7-8,共2页 Journal of Anhui Agricultural Sciences
关键词 苹果酸阿莫曲坦 含量测定 Almotriptan malate Content determination HPLC
  • 相关文献

参考文献1

二级参考文献10

  • 1KEAM SJ, GOA KL, FIGGITT DP. Almotriptan,a review of its use in migraine[J]. Drugs,2002,62(2) :387-414.
  • 2PALACIOS JM, RABASSEDA X, CASTANER J, et al. Almotriptan. Antimigraine,5-HT IB/ID agonist[ J]. Drugs Future, 1999,24(4) :367 -374.
  • 3BROOKE DF. Review of almotriptan: a 5-HTIB/ID agonist[J].Drug Forecast ,2002,27 (2) : 83 - 94.
  • 4DOWSON A J, MASSION H, LAINEZ JM, Almotriptan improves response rates when treatment is within 1 hour of migraine onset [J]. Headache, 2004,44 ( 4 ) :318.
  • 5GBAS J, LLENAS J, JANSAT JM, et al. Almotriptan, a new anti-migraine agent : s review [ J ]. CNS Drug Rev, 2002,8 ( 3 ) :217 -234.
  • 6MONDELL BE. A review of the effects of almotriptan and other triptans on clinical trial outcomes that are meaningful to patients with migraine[J].Clin Ther,2003,25(2):331-341.
  • 7BABTELS CL, DAUENHAUEB DL. Almotriptan for use in migraine [ J ]. Drug Inf Ser,2002,6 ( 6 ) : 1 - 3.
  • 8KEVIN WM, JANE TO. Health outcomes evaluations;estimating the impact of almotriptan in managed care settings[J]. Am J Man Care,2002,8 ( 3 ) : 85 - 93.
  • 9FLEISHAKER JC, RYAN KK, JANSAT JM, et al. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan,an antimigraine agent in hunmans[ J]. Br J Clin Pharmacol,2001,51(5) :437 -441.
  • 10刘德臣,姜爱丽,郭清华.N,N-二甲基色胺衍生物合成研究[J].精细化工,2002,19(7):385-387. 被引量:4

共引文献5

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部